Profile picture

Professor Steven E Nissen

Cleveland Clinic Hospital, Cleveland (United States of America)
Membership: ESC Professional Member
Follow
Biography
Prof. Steven E. Nissen MD MACC is Chief Academic Officer for the Heart and Vascular Institute at the Cleveland Clinic, Lewis and Patricia Dickey Chair and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine. From 2006 to 2019, he served as Chair of the Department of Cardiovascular Medicine. In 2006-2007 he served as President of the American College of Cardiology. Dr. Nissen manages C5R Research, an organization at the Cleveland Clinic that partners with industry in conducting clinical trials. He specializes in lipid-metabolic, diabetes and obesity trials, but has directed trials as study chair for clinical trials in multiple areas of cardiovascular medicine. He does not accept honoraria or other compensation from industry to stay completely independent. In 2007, Time Magazine selected Dr. Nissen as one of the world’s 100 most influential people. Beginning in 2015, he was named by Thompson-Reuters as one of the world’s most highly cited physician-scientists.
Logo ESC

Contributor content

Obesity (1)
Session
Obesity (1)
30 August 2025
Lipoprotein(a)  (1)
Session
Lipoprotein(a) (1)
29 August 2025
Risk factors - Obesity
Session
Risk factors - Obesity
29 August 2022
Diabetes and the Heart 3
Session
Diabetes and the Heart 3
29 August 2022
New insights for acute coronary syndrome pharmacotherapy
Session
New insights for acute coronary syndrome pharmacotherapy
31 August 2019
Cardiovascular risk reduction and dyslipidaemia management: current state and future therapies
Session
Cardiovascular risk reduction and dyslipidaemia management: current state and future therapies
27 August 2017
Prevention 360: Strategies for Managing Cardiovascular Risk
Session
Prevention 360: Strategies for Managing Cardiovascular Risk
28 August 2016
Current and future therapeutic options targeting residual Cardiovascular Disease (CVD) risk: emerging therapies for the treatment of dyslipidemia
Session
Current and future therapeutic options targeting residual Cardiovascular Disease (CVD) risk: emerging therapies for the treatment of dyslipidemia
31 August 2015

ESC 365 is supported by